888: UCYT+/Immunocyt™ in the Detection of Recurrent Urothelial Carcinoma: An Update on 1,991 Analyses

Mian, Christine; Maier, Klaus; Comploj, Evi; Lodde, Michele; Berner, Lucas; Lusuardi, Lukas; Palermo, Salvatore; Vittadello, Fabio; Pycha, Armin

doi:10.1016/s0022-5347(18)33124-0

Cited by 21 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specificity of the combined assay reaches 61.0%-77.7%, which is less than that offered by cytology alone. 27,[31][32][33]38,39 The ImmunoCyt/uCyt+ assay requires technical expertise, extensive sample handling and preparation and specialized equipment. However, a person with minimal cytology training and experience can perform the test.…”

Section: Immunocyt/ucyt+mentioning

confidence: 99%

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

127

View full text Add to dashboard Cite

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.Results: Sensitivity and specificity ranges, respectively, for each marker were reported as follows: BTA Stat (Polymedco), 52.5%–78.0% and 69.0%–87.1%; BTA Trak (Polymedco), 51%–100% and 73%–92.5%; cytology, 12.1%–84.6% and 78.0%–100%; hematuria dipstick, 47.0%–92.6% and 51.0%–84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%–100% and 60.0%–95.0%; NMP22 BladderChek (Matritech), 49.5%–65.0% and 40.0%–89.8%;ImmunoCyt/uCyt+ (DiagnoCure), 63.3%–84.9% and 62.0%–78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%–89.3% and 61.0%–77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%–100% and 65.0%–96.0%.Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

show abstract

Section: Immunocyt/ucyt+mentioning

confidence: 99%

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

127

View full text Add to dashboard Cite

show abstract

“…All 10 studies, reported in 12 papers, 101,[109][110][111][112][113][114][115][116][117][118][119] were diagnostic cross-sectional studies. Six reported consecutive recruitment.…”

Section: Immunocyt Characteristics Of the Included Studiesmentioning

confidence: 99%

“…In nine studies 101,[109][110][111][112][113][114]116,118 reporting this information, 890 participants (27%) presented with a suspicion of bladder cancer and 2405 (73%) had previously diagnosed bladder cancer. In one of these studies 118 the whole patient population (n = 301) had a suspicion of bladder cancer and in three 110,111,113 the whole population had previously diagnosed bladder cancer (n = 1499). One study 119 did not report this information.…”

Section: Immunocyt Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Across six studies 101,109,[112][113][114]116 providing information on patient age for the participant group as a whole, the median (range) of means was 68 years (66 to 73 years). Four studies 112,114,116,118 provided information on the gender of 1371 participants, of whom 1076 (78%) were men and 295 (22%) were women.…”

Section: Immunocyt Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Six studies [111][112][113][114]118,119 gave details of when they took place, with an earliest start date of November 1997 112 and latest end date of July 2007.…”

Section: Immunocyt Characteristics Of the Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

255

207

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. F...

show abstract